• Robert W. Baird set a price target of $95 for NASDAQ:MIRM, indicating a potential upside of approximately 6.15%.
• Mirum's preliminary unaudited results for 2025 show significant commercial growth and momentum in its pipeline.
• The stock's recent price movement, with a high of $90.07, reflects investor confidence and the market's positive response to the company's developments.

Mirum Pharmaceuticals, traded on the NASDAQ under the symbol MIRM, is a biopharmaceutical company based in Foster City, California. The company focuses on developing and commercializing therapies for rare liver diseases. As of January 12, 2026, Robert W. Baird set a price target of $95 for NASDAQ:MIRM, while the stock was priced at $89.50, indicating a potential upside of approximately 6.15%.

Mirum's recent preliminary unaudited results for 2025 highlight significant commercial growth and momentum in its pipeline. This strong performance suggests a positive trajectory for the company's business operations and future prospects. The stock's current price of $89.50 reflects an increase of approximately 3.38%, with a change of $2.93, showcasing investor confidence in the company's growth potential.

The stock has experienced fluctuations, with a low of $82 and a high of $90.07 today, the latter marking its highest price over the past year. The lowest price for MIRM in the past year was $36.88, indicating substantial growth. This price movement reflects the market's response to Mirum's promising developments and strategic initiatives.

Mirum Pharmaceuticals has a market capitalization of approximately $4.42 billion, underscoring its significant presence in the biopharmaceutical industry. The trading volume for MIRM is 1,229,452 shares, indicating active investor interest and engagement. This level of trading activity suggests that investors are closely monitoring the company's progress and potential for future growth.